Newsletter · 2026-10-05 · Ashutosh Agarwal

Lilly Sweeps the EASD Diabetes Meeting as Novo Bets on a Weekly Pill - The Obesity-Drug Pipeline - Week of October 5, 2026

The Obesity-Drug Pipeline, Issue #11, for the week of October 5, 2026. Podcast synthesis on Lilly dominating the EASD diabetes meeting with retatrutide at 28.3% and an amylin combination at about 23%, Novo's $300 million bet on an untested once-weekly pill, the Viatris patent challenge running to 2038, the shrunken GLOBE pricing rule, and stock-by-stock read-throughs across LLY, NVO, VTRS, REGN and AMGN.

The Obesity-Drug Pipeline

Week of October 5, 2026: Lilly Sweeps the EASD Diabetes Meeting as Novo Bets on a Weekly Pill

TL;DR (15 seconds)

• Lilly owned the European diabetes meeting (EASD, in Milan). Retatrutide's full Phase 3 paper showed 28.3% average weight loss at 80 weeks on the top dose and about 30% by week 104 in heavier patients. Its new amylin + tirzepatide combination hit about 23% at 48 weeks in people with diabetes, against about 15% for tirzepatide alone. A Bloomberg Intelligence analyst called everything else at the meeting "a bit of a meh." On The Pen GLP-1 News · Squawk on the Street · Biotech Hangout
• Novo answered with a cheque, not data. It paid $300 million upfront (up to $2.6 billion in total) to China's Hengrui for HRS-1596, a GLP-1/GIP drug designed as a once-weekly pill. The molecule has not yet started Phase 1. On the same podcast, Viatris was reported to be challenging a Novo semaglutide weight-management patent that runs to October 2038. On The Pen GLP-1 News
• On price, the government's tough-sounding drug-pricing model largely fizzled. Medicare's final GLOBE international-pricing rule exempts companies that already signed pricing deals with the administration. That leaves about four manufacturers in scope, and projected savings fell from $11.9 billion to $400 million. Medicare patients, meanwhile, are getting GLP-1s for about $50 a month through the bridge program. Citeline Podcasts (Pink Sheet "Drug Fix") · The Dr. Francavilla Show

How to read this issue: We label a speaker OPERATOR/INSIDER when they run, or ran, a company in the industry, or hold a direct commercial seat in it. Everyone else (journalists, investors, sell-side analysts, doctors, podcast hosts) is labeled ANALYST/PUNDIT, with their day job. This was a conference week, so most of the hard numbers came from Lilly's own presentations, relayed by journalists and doctors. No CEO of Lilly or Novo spoke on the record in this week's podcasts. Our sweep pulled 26 episodes. About half were patient, clinical, or Medicare-insurance shows with little or nothing on the drug business, and we left those out.

What's new

Ranked by how much each item matters for a portfolio.

1. Retatrutide's full Phase 3 paper: the headline is huge, but the important number may be the lowest dose. Retatrutide is Lilly's "triple" shot. It hits three gut-hormone receptors (GLP-1, GIP and glucagon), one more than tirzepatide (Zepbound/Mounjaro). The top-line result came out earlier. This week the full TRIUMPH-1 paper was published in the New England Journal of Medicine, and two podcasts went through it.

On On The Pen GLP-1 News, "They TRIPLED Wegovy Dose, Does it Beat Zepbound?" (October 1), host Dave Knapp (ANALYST/PUNDIT: patient advocate and GLP-1 commentator) gave the 80-week numbers on the "efficacy estimate" (the result for patients who stayed on the drug as prescribed): 19% weight loss on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg. In an extension for people who started with a BMI of at least 35, those staying on the top dose reached "around 30% average weight loss in 104 weeks." His verdict: "the largest average number of weight loss that we've ever seen from an obesity medicine."

What makes the paper more than a bigger number is the 4 mg dose. At 19%, it already matches what Zepbound's top dose delivers (about 20%), at one-third of retatrutide's maximum. Knapp's point: "If four milligrams of retatrutide gives someone enough benefit, that person may never need 12 milligrams." He also noted that side effects and dropouts rose with each dose step: "The highest dose produced the greatest average weight loss, but also came with the most people deciding that they needed to stop treatment because of adverse events." And a meaningful group of patients ended up with a BMI under 25, which means "they're below the BMI that even qualifies for the drug." That is a strange new problem for doctors and insurers.

The cardiology view was enthusiastic, with one flag. On This Week in Cardiology (October 2), Dr. John Mandrola (ANALYST/PUNDIT: cardiologist, Medscape host) described the 2,400-patient trial: the 9–12 mg doses produced "a 24–25% reduction in body weight versus 4% for placebo... A 250-pound person becomes a 200-pound person in about a year." (His figure differs from Knapp's because the paper reports results more than one way. Treat ~24–28% as the honest range for the top doses.) He listed the side benefits: "a 10-millimeter systolic blood pressure drop," big falls in LDL cholesterol, triglycerides and CRP (a marker of inflammation), and prediabetes falling "from 39% to 6%." Knee pain and sleep apnea both improved. The flag: resting heart rate rose by 7 and 9 beats per minute on the highest doses. The glucagon part of the drug stimulates the heart. Mandrola said that "should give us pause" for patients with HFrEF (heart failure where the heart pumps weakly), and "we need more data." Knapp made the same point: the pulse rise peaks during dose increases, then eases.

Why it matters: Retatrutide is no longer only a "more weight loss" story. A low dose that matches Zepbound with fewer side effects could make it a broad, first-line drug rather than a niche product for the very heavy. That is a much bigger market, and it is all Lilly's. The heart-rate signal is the thing regulators will look at, and it is the first real risk in an otherwise clean dataset. The court fight over whether retatrutide is regulated as a biologic, which affects how long competitors are kept out, still had no reported outcome on this week's podcasts.

2. Lilly's amylin combination posted about 23%, and the market's sharpest analyst says it was the only exciting thing at EASD. On Squawk on the Street (September 30), CNBC reporter Annika Kim Constantino (ANALYST/PUNDIT: health journalist, relaying Lilly's statements) broke the news. Lilly paired its experimental amylin drug (amylin is a hormone that signals fullness) with tirzepatide in a mid-stage trial of patients with obesity and type 2 diabetes. The combination produced weight loss of "up to roughly 23 percent... at 48 weeks," compared with "nearly 15 percent weight loss caused by a high dose of tirzepatide alone." Blood sugar also improved more. Side effects were higher. Lilly told her not to read too much into that at Phase 2 and said it would refine dosing in "phase 3 trials that will begin at the end of this year." Lilly pitched the combination for "people who didn't respond to or see the results that they wanted on existing GLP-1 products."

Why 23% in diabetics is a big deal: people with type 2 diabetes usually lose noticeably less weight on these drugs than people without it. On Biotech Hangout, Episode 198 (October 2), Sam Fazeli (ANALYST/PUNDIT: Bloomberg Intelligence pharma analyst) said: "I don't think we'd ever seen 23%... weight loss at that time point. Now, obviously, your discontinuation rates was quite high." Then came the line of the week for anyone holding a competitor: "Lilly is firing on all cylinders here... pretty much every other data point was a bit of a meh." He added that friends "who are not super obese" are already asking him "when is this triple thing coming to market."

Why it matters: Lilly now has two different routes past 20% weight loss: the triple (retatrutide) and the GLP-1/GIP/amylin combination. Amylin was supposed to be Novo's area of strength, through CagriSema and amycretin. Lilly is now competing on Novo's best ground, with better numbers in a harder patient group.

3. Zepbound vs. triple-dose Wegovy: Lilly's comparison says it still wins, but how big the win is depends on which statistics you use. Novo's answer to Zepbound has been to triple Wegovy's dose to 7.2 mg ("Wegovy HD"). At EASD, Lilly presented a paper comparison (not a head-to-head trial) of its SURMOUNT-1 data against Novo's STEP UP trial. Knapp on On The Pen GLP-1 News took it apart:

• "Treatment regimen" estimate (counts everyone, including those who quit, so closer to real life): tirzepatide 15 mg beat semaglutide 7.2 mg by 4.5 percentage points, and 10 mg by 3.2 points. Patients on 15 mg had "more than three times the odds" of losing at least 20% of body weight.
• "Efficacy" estimate (only those who stayed on the drug): the gap shrank to 1.8 points for 15 mg and 0.7 points for 10 mg. "Neither of those... reach statistical significance."

His summary: "the answer is going to change depending on the question you ask of the data." Turning semaglutide up to 7.2 mg "may not completely close the gap with tirzepatide, but it gets pretty close." For context, he cited the real head-to-head trial at standard doses: tirzepatide 20.2% vs Wegovy 2.4 mg 13.7% at 72 weeks.

Lilly ran the same kind of comparison for pills. Its pill Foundayo (orforglipron) was associated with 1.5 points more weight loss and 0.3 points more A1C reduction (A1C measures average blood sugar) than oral semaglutide 25 mg in diabetics at 52 weeks, with other methods giving ranges of 1.5–2.4 points and 0.3–0.6 points. In Lilly's actual head-to-head trial (ACHIEVE-3) against the lower 14 mg oral semaglutide dose, Foundayo produced 9.2% vs 5.3% weight loss and an A1C drop of 2.2 vs 1.4 points. Knapp's fair caveat: Novo likely timed its higher doses so that Lilly's early trials would be "a little bit behind the times."

Why it matters: The real-world gap that patients and payers experience, which is probably closer to the 4.5-point figure, is what drives which drug gets prescribed. But high-dose Wegovy gives Novo a credible "close enough" pitch, especially if it comes in cheaper. Expect both companies to quote whichever number suits them.

4. Novo paid $300 million upfront for a pill that hasn't been tested in people. The bet may be on the delivery technology, not the molecule. Last week Novo's CEO said the company was "quite interested" in deals. This week came one, though it was not the Viking takeout markets had floated. Knapp on On The Pen GLP-1 News reported that Novo licensed HRS-1596 from China's Jiangsu Hengrui (600276 CH). HRS-1596 is a GLP-1/GIP drug "designed for potential once-weekly oral dosing," with $300 million upfront and up to $2.6 billion in milestones, plus royalties. The catch: "it hasn't even entered phase one."

His read is the interesting part. Today's Wegovy pill is a peptide (a protein-like molecule) that the gut barely absorbs. Knapp said "I believe 0.1%" gets into the bloodstream, which is why the pill "uses 10 times the amount of semaglutide per day" as the weekly shot and is "actually more expensive when you consider" the ingredient cost. A peptide pill that works once a week would fix Novo's biggest manufacturing problem. So: "maybe this acquisition on Novo's part today is a little bit more about the technology than the actual pill." He was careful to say Novo did not buy Hengrui's whole delivery platform, only the one molecule. He also took a shot at strategy: Novo has "been so myopically focused on amylin for so long that I think that they kind of lost the game" on GIP, the hormone that makes tirzepatide work.

Novo did have some real-world data. Per CNBC's Constantino on Squawk on the Street, Novo released data from Ro's telehealth platform showing that patients who switched from injections such as Zepbound or Wegovy to the Wegovy pill "continue to lose weight after they switch... and stay on treatment for three months." Her takeaway: "patients may not have to actually stay on injections forever."

Why it matters: Novo's oral strategy is the right idea, since pills widen the market (1.5 million patients on the Wegovy pill per last week's investor day). But the economics of the current pill are poor, and the fix costs $300 million upfront and is years away. Meanwhile Lilly's small-molecule pill is cheap to make today. For an investor, the Hengrui deal reads as an admission of the cost problem as much as a solution to it.

5. The patent fight just got longer: Viatris is challenging a Novo patent that runs to 2038. Also on On The Pen GLP-1 News, Knapp reported that Viatris (VTRS), through its Mylan unit, has asked a federal court in Delaware to clear the way for a future generic Wegovy. The target is US patent 12,551,536, issued in February 2026, which "is scheduled to run until October of 2038" and covers "the use of semaglutide for weight management." Mylan filed what's called a Paragraph IV certification, which is a formal claim to the FDA that the patent is invalid or that its generic doesn't infringe it.

Knapp was clear on what this does not mean: cheaper generics are "not right around the corner" either way. The fight is about "whether generic competition starts in 2030s or whether Novo patents can keep competitors out for a lot longer than that." Blockbusters are protected by "a whole fence of patents" on the molecule, the dose, the formulation and each use.

Why it matters: For weeks podcasts have argued about Novo's US cliff, with 2030–31 cited in one issue and 2032 in another. Those dates refer to the core molecule. A weight-management use patent to 2038 means that even after the molecule expires, a generic might not be able to market semaglutide for obesity, which is the indication that matters. If Novo wins, its obesity franchise lasts longer than the simple cliff math implies. If Viatris wins, the opposite. This is a real swing factor for long-term Novo models, and it is now in court.

6. Medicare's crackdown on drug prices mostly let the big drugmakers off, and seniors are paying about $50 a month. On Citeline Podcasts, "Drug Fix: CMS Finalizes GLOBE Model..." (October 2), Kathy Kelly (ANALYST/PUNDIT: Pink Sheet senior writer) explained the final GLOBE rule. GLOBE is a mandatory Medicare pilot that ties some drug prices to lower prices abroad. Companies already in a separate Medicaid "most favored nation" program (GENEROUS), meaning those that signed pricing deals with the administration, are excluded. That "leaves only about four manufacturers," named as Biogen, Takeda and Daiichi Sankyo based on the rule. Projected savings fell to $400 million over seven years from $11.9 billion in the draft. Her read: the rule worked mainly as "leverage... to bring manufacturers to the table." A related Medicare Part D pilot (GUARD) is still pending and may wait "until after the elections," partly because it "will actually raise costs for beneficiaries." One detail to watch: the exemption runs only while GENEROUS lasts (currently to September 2030), while GLOBE runs to March 2032.

On the patient side, Dr. Melanie Jay (ANALYST/PUNDIT: obesity-medicine physician) on The Dr. Francavilla Show (September 28) said eligible Medicare Part D patients can now get GLP-1s through the bridge program "for like $50 a month," against "$500 or more per month if you get it through other places." A rheumatologist on Rheumnow Podcast (September 30) gave the same $50 figure and told doctors to steer patients there, warning of "prior authorizations and paperwork." On The Plus SideZ (September 30), two Medicare patients (ANALYST/PUNDIT: patient hosts) described being denied twice before getting approved the third time "for a year. As long as the program is available."

Why it matters: Lilly and Novo, by implication, sit outside the four companies GLOBE still covers. The policy risk that worried investors a year ago has been largely traded away through voluntary deals. Medicare demand is real (last week Lilly's CEO cited ~700,000 new senior starts since July 1), and the low patient cost explains why. Price risk now comes from negotiated deals and employer pullback, not from GLOBE.

The debate

The bull case (steel-manned): The best drug of the next decade keeps getting better, and one company owns it. Retatrutide's lowest dose matches today's best drug at about 19%, and its top dose reaches about 28–30%, a range that until now only surgery achieved. Lilly has a second route past 20% (amylin + tirzepatide, about 23% even in diabetics) and a cheap-to-make pill gaining share. Each step widens the group of patients who benefit, from the very heavy to the moderately overweight with heart, liver or joint problems. The government's toughest pricing tool just shrank to four companies and $400 million in savings. Medicare is paying, and seniors pay about $50 a month. And the market is far from saturated: a consumer podcast cited 15 million US adults on these drugs, and Lilly's guidance was raised to $85–87 billion for 2026.

The bear case (steel-manned): The better the drugs get, the stranger the economics. If 4 mg of retatrutide is enough, many patients never move up the dose ladder, and some fall below the BMI that qualifies them for coverage. Heart-rate increases of 7–9 beats per minute give regulators a reason to restrict use in heart patients. Discontinuation rose at the higher doses of both retatrutide and the amylin combination. Real-world gaps between drugs are shrinking: tripled Wegovy comes within 1.8 points of Zepbound on one measure, which gives payers room to make the drugs compete on price. Novo is moving to direct-to-consumer, "weight loss" marketing ("Live Lighter," "Summer Glow Up") because insurance coverage has stalled. A STAT reporter warned that the drugs "seem... headed towards the over-the-counter direction." That would mean cash prices, not insurance-covered prices. The patent map remains contested (Viatris vs. a 2038 use patent), and an estimated 7 million Americans are still getting compounded supply.

My read (a framing, not a call): This week split the efficacy race from the commercial race. Lilly has effectively won on efficacy: it now holds both 20%+ routes, and the only open questions are safety and dosing. But the frontier has become too effective for the current payment system. When a 4 mg dose matches the incumbent and the top dose pushes patients out of the eligible BMI range, the debate shifts from "how much weight" to "how little drug, at what price, for how long." The company that makes the cheapest effective maintenance dose will set the industry's profit pool. On that question Lilly's small-molecule pill and low-dose retatrutide line up well, and Novo's peptide pill, even with the Hengrui bet, does not yet.

Stocks in play

Named this week: LLY, NVO, VTRS, REGN, Roche, AMGN, Boehringer Ingelheim (private), Jiangsu Hengrui (600276 CH), Corbus Pharmaceuticals, plus food names Hershey (HSY) and Conagra (CAG). Viking (VKTX) was not discussed this week.

Read-throughs

• Fast-followers (AMGN, VKTX, Roche): one week back in the news, then overshadowed. After Viking's maintenance data last week, the fast-followers were mostly absent. Amgen got only a clinician explainer on Back on Track (September 28), where Dr. Alicia Shelley (ANALYST/PUNDIT: physician host) framed MariTide's appeal as 12 or even 6 injections a year instead of 52. Viking was silent. Roche appeared only for dropping a muscle drug. Lilly's EASD numbers raise the bar for all of them. A dual-hormone drug at 12–19% now has to compete with a triple at 19% on its lowest dose. Boehringer's US pharma president, Brian Hilberdink (OPERATOR/INSIDER: President, US Human Pharma, Boehringer Ingelheim), on Citeline Podcasts (September 28), described entering a "hyper-competitive space" against "two companies... one of them with a market cap that floats around a trillion dollars and another one that is my former employer" (Novo). His strategy is to "go beyond pounds on the scale," which is how a challenger talks when it cannot win on weight loss. On Biotech Hangout, Greg Sivanovich (ANALYST/PUNDIT: biotech analyst, co-host) flagged Corbus Pharmaceuticals' CB1 drug, which he covers, as having "differentiated safety tolerability" that "got no credit."
• Muscle preservation: three programs, one problem. Regeneron's MRI data looked good, Roche quit its program, and on The Peter Attia Drive (September 28) Dr. Lloyd Klickstein (OPERATOR/INSIDER: founding CEO of Versanis, which developed bimagrumab and was bought by Lilly) gave rare inside detail on the BELIEVE trial. In about 507 patients, the high-dose bimagrumab + semaglutide combination produced "22, 23%" body-weight loss at 72 weeks, and "the fat loss was 45.7% of starting body fat. Now that's what you get with bariatric surgery." The downside: "an increase in LDL... about 20%." He confirmed Lilly "paused one study" but still has a combination study with tirzepatide on clinicaltrials.gov. The common problem, per Biotech Hangout's Brian Skorney (ANALYST/PUNDIT: biotech analyst, co-host): the FDA wants an outcome endpoint, not an MRI scan. Klickstein had the same frustration: "the registration decision is made on the basis of body weight loss."
• Contract manufacturing / fill-finish (CTLT, LNZA, TMO): no company named, but the ingredient-cost story got sharper. Knapp's point that the Wegovy pill uses about 10x the semaglutide of the shot, with only about 0.1% absorbed, is exactly why Novo paid for a better-absorbed weekly pill. If HRS-1596 or similar technology works, it would reduce future peptide-ingredient demand per patient. That is a long-dated negative for peptide contract manufacturers and neutral-to-positive for small-molecule makers. No podcast discussed a contract manufacturer by name. Quiet for the sixth straight week.
• Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize): silent again. No device maker was named. The direction of travel is still unhelpful for pens: Novo's real-world data argues patients can switch from shots to pills, and the next wave pitches fewer injections (MariTide every 4–8 weeks). Still the quietest corner of the sector.
• Insurers / PBMs (CVS, CI, UNH): no tickers named, but coverage is retreating to government channels and cash. Medicare is paying (about $50 a month for patients), and the GLOBE rule spares the big manufacturers. Commercial coverage, by contrast, is the story Novo is marketing around. On The Readout Loud (October 1), STAT reporter Elaine (ANALYST/PUNDIT: STAT GLP-1 reporter) said "insurance coverage has stalled," so Novo has "increasingly turned to the direct-to-consumer channel," now explicitly calling its drugs "weight loss drugs" in ads with slogans like "Live Lighter" and "Summer Glow Up." Her warning for payers: if obesity is framed as cosmetic again, "we don't have that same expectation when people stop covering obesity drugs." That makes it easier for employers and insurers to keep dropping coverage, with less public backlash.
• Compounding / telehealth (read-through to HIMS and peers): still large, and federal pressure is building. The rheumatologist on Rheumnow Podcast cited an estimate that "7 million Americans are getting their GLP-1 drug online from a compounding source," naming celebrity-backed promotion (Serena Williams, Charles Barkley, Ro), and said "the government's about to shut down this... 503B loophole." That is his expectation, not a reported action. Boehringer's Hilberdink, an insider, said doctors have "kind of lost the obesity patient" to online pharmacies and telehealth. Telehealth is also a data source now: Novo's switching data came from Ro's platform.
• Medtech / bariatric: a smaller, more measured decline than last week's figure. The same Rheumnow episode cited bariatric-society data showing surgeries fell about 23% from 2022 to 2024 (230,000 to 177,000), with "less than 1 percent" of eligible patients choosing surgery. Last week a different panel said surgery was down "30, 40 percent." The new figure is more specific, so treat ~23% as the better anchor. The speaker argued surgery still has "greater durability," but Klickstein's bimagrumab data (45.7% fat loss, "what you get with bariatric surgery") goes straight at that last advantage. Also from Rheumnow: in the TOGETHER-PsO study, Taltz + Zepbound hit the combined skin/weight goal in 31% of patients at week 52 vs 4% on Taltz alone. That is a Lilly-on-Lilly combination that widens tirzepatide's use in inflammatory disease.
• Food / QSR: the best evidence in weeks, and real operator data. On The CPG Guys (September 30), the hosts (ANALYST/PUNDIT: consumer-goods industry commentators) revisited a Cornell study: households with a GLP-1 user cut grocery spending by about 6% within six months, and about 9% in higher-income households ($690 a year vs $416 for the average affected household). Savory snacks fell 11%, with chips, baked goods and cookies down 6.7–11.1%. Baskets got healthier "mostly by subtraction." They cited about 15 million US adults on GLP-1s. Hershey (HSY)'s CEO calls the impact "mild so far." Conagra (CAG) now labels Healthy Choice meals "GLP-1 friendly," the first major brand to put that on the pack. Nestlé has launched products for this group. Morgan Stanley's $105 billion global obesity-drug market forecast for 2030 was cited. The best datapoint came from a restaurant. On The Restaurant Innovator (September 30), the CEO of Emmy Squared Pizza (OPERATOR/INSIDER: restaurant chain CEO) said its "Skinny Square," "half the dough, all the flavor," launched "to address GLP-1," and "within a week to two weeks... took over 20 to 25% of our sales of pizzas." The chain also sells a half-size cocktail ("the shorty") because "people aren't drinking as much." This is how restaurants adapt: smaller portions at lower prices. Expect the revenue per visit to suffer before the visit counts do.

What changed vs last week

Issue #10 (September 28) was about the fast-followers coming back (Viking's monthly maintenance data), Novo's flat investor day and open interest in acquisitions, and Lilly's Medicare numbers. Here is what changed.

• Biggest change: EASD happened, and Lilly dominated it. Last week we flagged EASD as "the next place to watch." It delivered: retatrutide's full paper, the amylin + tirzepatide 23% result, and two Lilly comparisons (Zepbound vs Wegovy 7.2 mg, Foundayo vs oral semaglutide 25 mg). The Regeneron muscle data we listed as a catalyst also came out (MRI muscle retention, but endpoint questions).
• Novo's M&A talk turned into a deal, but a small, early one. Last week the CEO said Novo was "quite interested" in deals, and a podcast panel floated a $7.5–8 billion Viking takeout. This week Novo instead licensed a not-yet-in-humans weekly pill for $300 million upfront. The bid under mid-cap obesity names is weaker than last week's chatter implied. Viking was not mentioned anywhere this week.
• Patent-cliff debate: new information. Last week we flagged a conflict (2030–31 vs 2032 for Novo's US semaglutide cliff). This week added a third date: a weight-management use patent to October 2038, now challenged by Viatris. The molecule dates and the use-patent date are different things, and the 2038 patent matters most for the obesity indication.
• Confirmed: Medicare is a cheap, growing channel (last week $245–260 government price; this week about $50 a month patient cost from two doctors). Compounding remains large and under pressure (Empower warning letter last week; a "7 million" user estimate this week). The broad benefits beyond weight keep growing (retatrutide improved blood pressure, CRP, sleep apnea and knee pain; the TOGETHER-PsO psoriasis combination).
• Contradicted / revised: The bariatric decline is now cited at ~23% (2022–2024) rather than last week's "30, 40 percent." We prefer the more specific new figure. On the payer split: last week we framed employers as leaving and government as staying. This week's evidence (Novo's consumer-marketing pivot) suggests the manufacturers are themselves accepting the commercial retreat and going direct to patients.
• Catalyst status: Retatrutide biologic-status ruling: still no outcome reported on podcasts. Foundayo diabetes FDA decision: not discussed this week. CagriSema approval: not discussed this week. GLOBE rule: resolved, and it largely spared the big manufacturers. GUARD (Part D): pending, possibly after the midterms.
• New this week: Retatrutide's full dose-by-dose results and heart-rate signal. Amylin + tirzepatide at 23%. The EASD comparisons. Novo–Hengrui HRS-1596. Novo's Ro switching data. The Viatris patent challenge. The final GLOBE rule. Boehringer's survodutide strategy and SYNCHRONIZE-2 data. Bimagrumab insider detail. Roche dropping its myostatin drug. Corbus's CB1 drug. Novo's consumer-marketing pivot. The Cornell grocery study and Emmy Squared's "Skinny Square."
• Went quiet: Viking (last week's top story, zero mentions). Employer carve-outs (last week's big payer theme, only indirectly via Novo's consumer pivot). Novo/Lilly CEOs (both spoke last week, neither this week).
• Still quiet (zero dedicated coverage): UBT-251; CagriSema news; Roche CT-388/CT-996 new data; named contract manufacturers (CTLT, LNZA, TMO); pen/injector makers (Ypsomed, Gerresheimer, Phillips Medisize); named PBMs (CVS, CI, UNH); TrumpRx details; Medicaid state actions; the Tennessee Fair Rx Act and other state laws; trials SUMMIT, SURMOUNT-OSA, FLOW, STEP-HFpEF and ESSENCE by name; Pfizer/Metsera and Structure; and, as every week, clean TRx/NRx counts with a real net price per script. Persistence came up only through dropout rates at high doses and Novo's three-month switching data.

The honest summary: last week the challengers had a good week. This week Lilly reminded everyone how far ahead it is. The remaining question is less about who can make patients lose the most weight and more about what the industry can charge once the drugs work so well that a third of the dose is enough.